Schuster will present data from a randomized, double-blind, phase III multicenter clinical trial on Monday, Dec. 6 at the annual meeting of the American Society of Hematology (ASH). ???Our work stands to revolutionize the approach to personalized vaccine development in lymphoma, and bring new hope to patients who are diagnosed with all types of the disease.